Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sucampo Pharmaceuticals, Inc.    SCMP

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/17/2017 07/18/2017 07/19/2017 07/20/2017 07/21/2017 Date
11(c) 10.85(c) 10.8(c) 10.9(c) 10.95(c) Last
446 800 330 981 572 531 348 062 215 601 Volume
+0.46% -1.36% -0.46% +0.93% +0.46% Change
More quotes
Financials ($)
Sales 2017 234 M
EBIT 2017 104 M
Net income 2017 35,0 M
Debt 2017 243 M
Yield 2017 -
Sales 2018 242 M
EBIT 2018 108 M
Net income 2018 51,8 M
Debt 2018 140 M
Yield 2018 -
P/E ratio 2017 14,28
P/E ratio 2018 11,77
EV / Sales2017 3,22x
EV / Sales2018 2,68x
Capitalization 509 M
More Financials
Company
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in developing, identifying, acquiring and bringing medicines that meet unmet medical needs.It focuses on gastroenterology, ophthalmology, and oncology-related disorders.The company's product pipeline includes AMITIZA for... 
More about the company
Surperformance© ratings of Sucampo Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on SUCAMPO PHARMACEUTICALS, I
07/19 SUCAMPO PHARMACEUTICALS, INC. (NASDA : SCMP) Files An 8-K Departure of Directors..
07/19 SUCAMPO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Regul..
07/19 Sucampo Announces Second Quarter 2017 Earnings Call
07/18 Dr. Karen Smith Joins Sucampo’s Board of Directors
06/13 Sucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270
06/06 SUCAMPO PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Chan..
06/01 Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Jefferie..
05/22 SUCAMPO PHARMACEUTICALS : Financial Statements and Exhibits (form 8-K/A)
05/22 SUCAMPO PHARMACEUTICALS : Technical Reports on Drug Makers Stocks -- Synergy Pha..
05/15 SUCAMPO PHARMACEUTICALS : Cerecor Appoints Steven Boyd and Peter Greenleaf to Bo..
More news
Sector news : Bio Therapeutic Drugs
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/12 FDA panel backs Novartis' pioneering new cancer gene therapy
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on SUCAMPO PHARMACEUTICALS, I 
2015The bullish trend is not over
More Strategies
Latest Tweets
07/20BRIEF-Sucampo Pharmaceuticals says board voted to increase authorized size of.. 
07/19Sucampo Pharmaceuticals $SCMP Given Daily Media Sentiment Score of 0.20  
07/16Sucampo Pharmaceuticals $SCMP Earning Somewhat Positive Press Coverage, Repor.. 
07/15$0.22 Earnings Per Share Expected for Sucampo Pharmaceuticals, Inc. $SCMP Thi.. 
07/13Karp Capital Management Corp Takes Position in Sucampo Pharmaceuticals, Inc. .. 
More tweets
Qtime:20
News from SeekingAlpha
05/23 Sucampo Pharmaceuticals (SCMP) Presents At Bank of America Merrill Lynch 2017..
05/03 Sucampo Pharmaceuticals' (SCMP) CEO Peter Greenleaf on Q1 2017 Results - Earn..
05/03 Sucampo Pharmaceuticals, Inc. 2017 Q1 - Results - Earnings Call Slides
05/03 Sucampo Pharma Q1 revenues up 19%; updates guidance
05/03 Sucampo misses by $0.04, beats on revenue
Chart SUCAMPO PHARMACEUTICALS, I
Duration : Period :
Sucampo Pharmaceuticals, I Technical Analysis Chart | SCMP | US8649091068 | 4-Traders
Technical analysis trends SUCAMPO PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 18,3 $
Spread / Average Target 67%
EPS Revisions
Managers
NameTitle
Peter S. Greenleaf Chairman & Chief Executive Officer
Peter P. Pfreundschuh Chief Financial Officer
Peter Lichtlen Chief Medical Officer
Peter Alec Kiener Chief Scientific Officer
Matthew Maxwell Donley EVP-Human Resources & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
SUCAMPO PHARMACEUTICALS, INC.-19.19%509
AMGEN23.25%132 526
CELGENE CORPORATION19.00%107 551
GILEAD SCIENCES3.00%96 384
REGENERON PHARMACEUTICALS40.54%54 837
VERTEX PHARMACEUTICALS121.49%40 641